Azacitidine and nivolumab combo proves successful in phase II trial

pharmafile | November 13, 2018 | News story | Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas 

A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or refractory acute myeloid leukaemia (AML) in a phase II trial, led by Professor Naval Daver the University of Texas MD Anderson Cancer Center.

The phase II trial demonstrated that 22% of the 70 patients went into complete remission following the combination treatment. While participants had on average already undergone two prior treatments for relapsed AML, the response rate was 33% overall.

However around 11% of patients suffered from severe or potentially life threatening side effects, the majority of which were treated successfully. The average overall survival was just over 6 months. Due to the encouraging results, researchers have initiated a phase III trial.

Daverat commented: “We believe that implementation of clinical and immune biomarkers to select patients are likely to yield further improved outcomes with these types of therapies in AML.

Louis Goss

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT …


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …

Latest content